Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Acorda Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
- Exchange
- nasdaq
- Notice
- delisting notice
- Rules
- 5101, 5110(b), IM-5101-1
Exact text from the filing
April 3, 2024, the Company was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the “Common Stock”) from Nasdaq. Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of the Chapter 11 Case. Nasdaq also notified the Company, as a separate basis for delisting, that the Company was not in compliance with Listin
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Acorda Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- stockholders equity
- Rules
- 5450(b)(1)(A)
Exact text from the filing
April 3, 2024, the Company was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the “Common Stock”) from Nasdaq. Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of the Chapter 11 Case. Nasdaq also notified the Company, as a separate basis for delisting, that the Company was not in compliance with Listin
View on SEC.gov